India, April 8 -- AtaiBeckley Inc. (ATAI) has reported new Phase 2a data showing that a single intranasal dose of its investigational therapy BPL-003 produced a rapid and durable antidepressant response in adults with treatment-resistant depression who remained on stable SSRI therapy.
Treatment-resistant depression affects roughly 30% of people living with major depressive disorder and is defined as failing to respond to at least two prior antidepressants. For many patients, symptoms persist for years, and available treatments often require multiple doses, long clinic visits, or have delayed onset.
In the open-label Phase 2a study, published in CNS Drugs, 66.7% of participants (8 out of 12) achieved an antidepressant response-defined as a...